CA2260771A1 - Procede servant a provoquer la vasodilatation et a traiter l'hypertension pulmonaire au moyen du transfert provoque par adenovirus du gene de synthase d'oxyde nitrique - Google Patents

Procede servant a provoquer la vasodilatation et a traiter l'hypertension pulmonaire au moyen du transfert provoque par adenovirus du gene de synthase d'oxyde nitrique Download PDF

Info

Publication number
CA2260771A1
CA2260771A1 CA 2260771 CA2260771A CA2260771A1 CA 2260771 A1 CA2260771 A1 CA 2260771A1 CA 2260771 CA2260771 CA 2260771 CA 2260771 A CA2260771 A CA 2260771A CA 2260771 A1 CA2260771 A1 CA 2260771A1
Authority
CA
Canada
Prior art keywords
pulmonary
nitric oxide
oxide synthase
pulmonary hypertension
gene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA 2260771
Other languages
English (en)
Inventor
Stefan Janssens
Kenneth D. Bloch
Desire Collen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
KU Leuven Research and Development
General Hospital Corp
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2260771A1 publication Critical patent/CA2260771A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0071—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14)
    • C12N9/0073—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14) with NADH or NADPH as one donor, and incorporation of one atom of oxygen 1.14.13
    • C12N9/0075—Nitric-oxide synthase (1.14.13.39)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/027—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a retrovirus

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne un procédé de thérapie génique servant à provoquer la vasodilatation pulmonaire. Elle consiste, plus spécifiquement, à introduire le gène de synthase d'oxyde nitrique dans les poumons, ce qui provoque la vasodilatation pulmonaire. Ceci exerce un effet d'hypotension sur la circulation pulmonaire et n'affecte pratiquement pas la pression sanguine systémique ni l'indice cardiaque. Ce procédé est utile pour traiter l'hypertension pulmonaire primaire ou consécutive à différentes maladies.
CA 2260771 1996-07-17 1997-07-17 Procede servant a provoquer la vasodilatation et a traiter l'hypertension pulmonaire au moyen du transfert provoque par adenovirus du gene de synthase d'oxyde nitrique Abandoned CA2260771A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2191296P 1996-07-17 1996-07-17
US60/021,912 1996-07-17

Publications (1)

Publication Number Publication Date
CA2260771A1 true CA2260771A1 (fr) 1998-01-22

Family

ID=21806802

Family Applications (1)

Application Number Title Priority Date Filing Date
CA 2260771 Abandoned CA2260771A1 (fr) 1996-07-17 1997-07-17 Procede servant a provoquer la vasodilatation et a traiter l'hypertension pulmonaire au moyen du transfert provoque par adenovirus du gene de synthase d'oxyde nitrique

Country Status (3)

Country Link
EP (1) EP0979088A4 (fr)
CA (1) CA2260771A1 (fr)
WO (1) WO1998002170A1 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4411402A1 (de) * 1994-03-31 1995-10-05 Juergen Schrader DNA-Expressionsvektoren zur Verwendung in der gentherapeutischen Behandlung von Gefäßerkrankungen
EP1016727A1 (fr) * 1998-12-30 2000-07-05 Introgene B.V. Thérapie génique ayant pour but la promotion de l' angiogenèse
EP1016726A1 (fr) * 1998-12-30 2000-07-05 Introgene B.V. Thérapie génique pour la promotion de l' angiogenèse
ATE364387T1 (de) * 1999-09-23 2007-07-15 An Go Gen Inc Zellbasierte gentherapie für das lungensystem
AU2001288518A1 (en) * 2000-08-30 2002-03-13 Primecyte, Inc. Methods for treating tumors using sulfonyl compounds
EP1348434A1 (fr) * 2002-03-27 2003-10-01 Fujisawa Deutschland GmbH Utilisation de pyridylamides comme inhibiteurs de l'angiogenèse
US20080194491A1 (en) * 2002-12-24 2008-08-14 Stewart Duncan J Methods of Diagnosing, Preventing, and Treating Early Onset of Pulmonary Hypertension
DE102012220693A1 (de) 2012-11-13 2014-05-15 Trumpf Medizin Systeme Gmbh + Co. Kg Schutzeinrichtung für ein Bediengerät

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69133575T2 (de) * 1990-12-05 2008-04-17 The General Hospital Corp., Boston Verwendung von NO zur Behandlung der persistenten pulmonaren Hypertonie des Neugeborenen
US5498539A (en) * 1992-07-02 1996-03-12 Daiichi Pharmaceutical Co., Ltd. Bovine endothelial nitric oxide synthase nucleic acids

Also Published As

Publication number Publication date
EP0979088A1 (fr) 2000-02-16
WO1998002170A1 (fr) 1998-01-22
EP0979088A4 (fr) 2002-11-06

Similar Documents

Publication Publication Date Title
Janssens et al. Adenoviral-mediated transfer of the human endothelial nitric oxide synthase gene reduces acute hypoxic pulmonary vasoconstriction in rats.
JP3778930B2 (ja) 動脈平滑筋細胞増殖の抑制
Kitamura et al. Gene transfer into the rat renal glomerulus via a mesangial cell vector: site-specific delivery, in situ amplification, and sustained expression of an exogenous gene in vivo.
CA2343575C (fr) Inhibition de la migration des cellules des muscles lisses au moyen de l'heme oxygenase (1)
Kopfler et al. Adenovirus-mediated transfer of a gene encoding human apolipoprotein AI into normal mice increases circulating high-density lipoprotein cholesterol.
US7772367B2 (en) C-terminal p53 palindromic peptide that induces apoptosis of cells with aberrant p53 and uses thereof
US7888089B2 (en) eNOS mutations useful for gene therapy and therapeutic screening
JPH10501989A (ja) 疾患治療用誘導型一酸化窒素シンターゼ遺伝子
JPH08501686A (ja) 中枢神経系、特に脳における細胞への外来遺伝子の転移のためのアデノウィルスベクター
RO117861B1 (ro) Complex de acid nucleic si compozitie pentru introducerea acestuia in celulele eucariote superioare
Osborne et al. Design of vectors for efficient expression of human purine nucleoside phosphorylase in skin fibroblasts from enzyme-deficient humans.
JPH09504558A (ja) アデノウイルスベクターを使用する再狭窄の遺伝子治療
US6710037B2 (en) Method of treating androgen-dependent disorders
CA2260771A1 (fr) Procede servant a provoquer la vasodilatation et a traiter l'hypertension pulmonaire au moyen du transfert provoque par adenovirus du gene de synthase d'oxyde nitrique
JP4733337B2 (ja) ヒトのウロキナーゼ型プラスミノゲン活性化因子の遺伝子を含む組換えウイルスベクターおよび非ウイルスベクター、および肝線維症、腎線維症、肺線維症、膵線維症、心臓線維症などのさまざまなタイプの線維症、および肥厚性瘢痕の治療におけるその有用性
US6720309B1 (en) Method of inducing vasodilation and treating pulmonary hypertension using adenoviral-mediated transfer of the nitric oxide synthase gene
WO1995010623A1 (fr) Transfert selectif adenoviral de genes vers les cellules neointimales vasculaires
Gao et al. Intramuscular injection of an adenoviral vector expressing hepatocyte growth factor facilitates hepatic transduction with a retroviral vector in mice
JPH10502533A (ja) Ｎｏシンターゼをコードする遺伝子を含むアデノウイルス
NZ515233A (en) Use of a recombinant defective adenovirus comprising a nucleic acid encoding an angiogenic factor for treating pulmonary hypertension
Frey et al. Biochemical and functional characterization of nitric oxide synthase III gene transfer using a replication-deficient adenoviral vector
WO1999060149A1 (fr) Co-precipites d'adenovirus avec des sels de metaux
Chen et al. Functional influence of gene transfer of recombinant nitric oxide synthase to cardiovascular system
Rios et al. Ten steps to gene therapy for cardiovascular diseases
JPH10500859A (ja) 組換えウイルス、製造方法および遺伝子治療での使用

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead